Please assess the completion status of the following clinical trial:

Trial Title: Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* To be eligible for inclusion, each patient must fulfill each of the following criteria:~  1. Histologically confirmed adenocarcinoma of the rectum~ 2. Tumor located within 12cm of anal verge~ 3. Clinical stage of cT3-4Nany (cStage II) or cTanyN1-2 (cStage III) by rectal MRI~ 4. Available tumor samples for methylation-specific PCR (MSP) to investigate MGMT hypermethylation~ 5. Male or female aged over 20 years~ 6. Be ambulatory and have an Eastern Cooperative Oncology Group (ECOG) performance status0-1.~ 7. No prior systemic treatment (chemotherapy, immunotherapy) or radiation therapy~ 8. Adequate major organ functions as following:~     Hematopoietic function: ANC 1,500/mm3, Platelet 100,000/mm3 Hepatic function: serum bilirubin 2.0 mg/dL, AST/ALT levels 2.5 x UNL Renal function: serum creatinine UNL or Cockroft creatinine clearance 50 ml/min~ 9. Be willing and able to comply with the protocol for the duration of the study.~ 10. Give written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~Exclusion Criteria:~- Patients will be exluded from the study for any of the following reasons:~1. Histology other than adenocarcinoma or tumor arising from inflammatory bowel disease~2. Inadequate tumor sample for MGMT MSP~3. Any evidence of systemic metastasis~4. Unresected synchronous colon cancer; endoscopically resected synchronous colon cancer of pTis or pT1 is permitted~5. Subjects unable to swallow oral medication because of such as current or impending intestinal obstructions, but bypass surgery (colostomy or ileostomy) is permitted before study treatment~6. Uncontrolled or severe cardiovascular disease:~   * New York Heart Association class III or IV heart disease.~  * Unstable angina or myocardial infarction within the past 6 months.~  * History of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality.~7. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.~8. Other malignancy within the past 5 years except cured non-melanomatous skin cancer, carcinoma in situ of the cervix, or thyroid papillary carcinoma.~9. Organ allografts requiring immunosuppressive therapy.~10. Psychiatric disorder or uncontrolled seizure that would preclude compliance.~11. Pregnant, nursing women or patients with reproductive potential without contraception.~12. Patients receiving a concomitant treatment with drugs interacting with 5-FU such as flucytosine, phenytoin, or warfarin et al.~13. Known dihydropyrimidine dehydrogenase (DPD) deficiency.~14. Known hypersensitivity to any of the components of the study medications.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGMT hypermethylated Cohort A (Type: EXPERIMENTAL): MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
- MGMT hypermethylated Cohort B (Type: ACTIVE_COMPARATOR): MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
- MGMT unmethylated Cohort A (Type: ACTIVE_COMPARATOR): MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
- MGMT unmethylated Cohort B (Type: ACTIVE_COMPARATOR): MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)

Based on this trial design, predict the completion outcome and termination type (if applicable).